Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy-Reference-Cited by-同舟云学术

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy

Published:2017-12-08 Issue:26 Volume:1 Page:2541-2552
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Gong Zimu¹,Medeiros L. Jeffrey¹,Cortes Jorge E.²,Chen Zi¹,Zheng Lan¹,Li Yan¹,Bai Shi¹,Lin Pei¹,Miranda Roberto N.¹,Jorgensen Jeffrey L.¹,McDonnell Timothy J.¹,Wang Wei¹,Kantarjian Hagop M.²,Hu Shimin¹^ORCID

Affiliation:

1. Department of Hematopathology and

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract

Key Points CML patients can be stratified into 4 subgroups with different risk of blastic transformation based on cytogenetic abnormalities. TKI therapy mitigates risk of blastic transformation associated with low-risk ACAs or no ACAs but not that associated with HR ACAs.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/26/2541/880191/advances011858.pdf

Reference45 articles.

1. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia;Johansson;Acta Haematol,2002

2. Evaluation of survival data for chronic myelocytic leukemia;Sokal;Am J Hematol,1976

3. Chronic myelogenous leukemia: biology and therapy;Faderl;Ann Intern Med,1999

4. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008;Björkholm;J Clin Oncol,2011

5. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol,2016

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment‐free remission in CML patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations;American Journal of Hematology;2024-03-04

2. Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph‐positive B‐ALL and pose a diagnostic challenge;American Journal of Hematology;2024-01-19

3. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia;Leukemia;2023-10-04

4. Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH);Current Research in Translational Medicine;2023-10

5. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group;Clinical and Experimental Medicine;2023-09-25